Michael Ehlers is the founder of Ascidian Therapeutics and served as its President and Chief Executive Officer until July 2026, when he stepped down from the executive role and continued as Chair of the Board of Directors.
As Board Chair he guides scientific direction and company strategy for the RNA exon editing developer. He founded the company to pursue RNA exon editing as an alternative to permanent genome modification, and led it through venture financing rounds and a research collaboration with Roche.
Ehlers holds an M.D. and a Ph.D. and has spent his career in neuroscience research and biopharmaceutical leadership.
Facts compiled by Executive Moves from publicly available news and press releases on 22 July 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you Michael Ehlers?
This is a Light profile, auto-generated from public news coverage. Claim it to verify your bio, add a photo and links, and control how your career is represented on Executive Moves.
Claim this profile →
